期刊文献+

HPLC法测定恩替卡韦中的三种光学异构体 被引量:2

Determination of Three Optical Isomerisms of Entecavir by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法建检查恩替卡韦原料中的三种光学异构体。方法:使用Chiralpak AD-H手性柱(4.6mm×250mm,5μm),乙醇-甲醇-正庚烷-三乙胺(42.5∶2.5∶55∶0.1)为流动相,流速为每分钟0.6mL·min-1,检测波长为254nm。结果:3种异构体和恩替卡韦能够被有效分离。结论:本方法可较快的拆分恩替卡韦的3种异构体,可用来控制恩替卡韦原料药中异构体的限度。 Objective:To develop an HPLC method for the three optical isomerisms separation of entecavir. Methods: Chiralpak AD-H(4.6 mm×25 mm,5 μm)with the mobile phase consisting of ethanol-methanol-n-heptane-triethylamine (42.5∶2.5∶55∶0.1) was used. The wavelength was set at 254 nm and the flow rate was kept at 0.6 mL·min-1.Results: Three isomerisms were completely separated and determined. Conclusion: The method was quickly to separated the three isomerisms of entecavir. and was applicable to the purity determination of entecavir.
作者 曾洁
出处 《中国药品标准》 CAS 2010年第6期423-425,共3页 Drug Standards of China
关键词 恩替卡韦 光学异构体 HPLC Entecavir Optical isomerisms HPLC
  • 相关文献

参考文献3

二级参考文献48

  • 1周晔,冯芳,张正行.盐酸恩丹西酮的高效毛细管电泳手性分离及其大鼠体内立体选择性药动学研究[J].中国药学杂志,2006,41(7):541-544. 被引量:2
  • 2Colonno RJ, Genovesi EV, Medina L, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [ J] . J Infect Dis, 2001,184 (10): 1236.
  • 3Gish RG, LeungNWY, WrightTL, etal. Doserange study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection [ J] . Antimicrob Agents Chemother,2002, 46(6): 1734.
  • 4Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [ J] . J Virol, 2001,75(10):4771.
  • 5Van Bommel F, Schemick A, Hopf U, et al. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation [J] . Gastroenterology, 2003, 124(2):586.
  • 6Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed [J] . J Infect Dis,
  • 7Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) [ J]
  • 8Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir[J]. J Viral Hepat, 2000, 7(2): 161.
  • 9Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection[J]. N Engl J Med, 1995, 333(25): 1657.
  • 10Barcena MR, Cid GL, Lopez SP. Use ofadefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine [ J] . Transplant Proc, 2003,35(5):1841.

共引文献9

同被引文献13

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部